Astrazeneca Ab

William McCoull

Marianne Bernice Ashford

Edward John Hennessy

Michael Giannis

Brian Kelly

David Owen

John Paul Secrist

Iain Grant

James Stewart Scott

Clifford David Jones

Richard William Arthur Luke

Paul Robert Owen Whittamore

Martin John Packer

Roger John Butlin

Thorsten Nowak

Alleyn Thomas Plowright

Alan Martin Birch

Craig Samuel Donald

Suzanne Saxon Bowker

Barry Raymond Hayter

Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.

Therapeutic dendrimers

Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11&#x3b2;HSD1, processes for making them and pharmaceutical compositions comprising them are described.

Chemical compounds

Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example Ris optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; Ris an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described. 

Oxadiazole derivative as DGAT inhibitors

A compound of the formula(I); wherein the substituents are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man. The compounds are inhibitors Tie2 receptor tyrosine kinase (TEK). 

Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2

A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR; Z is selected from N and CR; Qis selected from optionally substituted aryl and heteroaryl, and the substituents Rto Rare as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

Condensed pyridines and pyrimidines with tie2 (TEK) activity

Growing community of inventors

Macclesfield, United Kingdom

William McCoull